One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results - ...

Shares in Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, ...

An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes.

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

The global capability centre of Novo Nordisk in India is now closely engaged with the entire value chain of this global ...

Novo Nordisk clarifies Human Mixtard penfill to be replaced with injectables: Our Bureau, Bengaluru Wednesday, April 23, 2025, 13:30 Hrs [IST] Denmark-based global pharma major, N ...

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ...